Skyrizi now PBS listed

For Community

For Fellows and Trainees

For Health Professionals

Posted 7 months ago

Skyrizi  (risankizumab) is now Pharmaceutical Benefits Scheme listed for the treatment of severe chronic plaque psoriasis.

The drug is an interleukin 23 (IL-23) inhibitor and is indicated for treatment  in adults who are candidates for phototherapy or systemic therapy.

Please review the Consumer Medicines Information here for further safety information.